Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents

INTRODUCTION: Nemolizumab, a new monoclonal antibody that targets the receptor alpha of the neuroimmune cytokine interleukin-31 (IL-31), has shown efficacy in atopic dermatitis (AD) in adults. This study evaluated the pharmacokinetics (PK) and safety of nemolizumab in adolescents with moderate to se...

Descripción completa

Detalles Bibliográficos
Autores principales: Sidbury, Robert, Alpizar, Sady, Laquer, Vivian, Dhawan, Sunil, Abramovits, William, Loprete, Luca, Krishnaswamy, Jayendar Kumar, Ahmad, Faiz, Jabbar-Lopez, Zarif, Piketty, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941010/
https://www.ncbi.nlm.nih.gov/pubmed/35088348
http://dx.doi.org/10.1007/s13555-021-00678-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941010/
https://www.ncbi.nlm.nih.gov/pubmed/35088348
http://dx.doi.org/10.1007/s13555-021-00678-7

Ejemplares similares